| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 22.8 | 20.8 |
| Profit before tax | -70.2 | -74.1 |
| Net income | -70.2 | -74.1 |
| EPS (diluted, $ a share) | $-0.78 | $-0.85 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | +10.1% |
|---|---|
| Operating margin | -326.9% |
10-Q filed with the SEC, NASDAQ: KURA. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Kura Oncology, Inc.: key numbers
- Share price
- $7.49Close, Nov 17
- Market cap
- $688M
- Shares outstanding
- 91.88MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Kura Oncology, Inc.
All →Kura Oncology President and CEO Troy Edward Wilson Buys $1.5M of Stock
Troy Edward Wilson, President and CEO, bought 200,000 shares of Kura Oncology, Inc. at $7.42 to $7.63 a share (average $7.52) in 2 transactions, worth $1.5M in total between Nov 13, 2026 and Nov 16, 2026. Shares held after the trade: 635,456 (+18.9%).
- Value
- $1.5M
- Shares
- 200,000
- Average price
- $7.52
- Role
- President and CEO
- Holding change
- +18.9%
- Trade date
- Nov 13, 2026 to Nov 16, 2026
Kura Oncology Financial Results
Kura Oncology reported Q3 2026 financial results, highlighted by $13.9 million in net product revenue for KOMZIFTI, representing 53% sequential growth. The company reached FDA alignment on a registrational study design for darlifarnib in salivary gland cancer and secured a strategic financing agreement with Oberland Capital for up to $300 million.
- Term
- Q3 2026
“KOMZIFTI delivered strong commercial performance this quarter, with 53% sequential revenue growth, a 30% increase in new patients starts, and continued majority share of new patient starts. We believe these results demonstrate the growing commercial potential of KOMZIFTI and provide a strong foundation as we advance ziftomenib into the substantially larger frontline AML opportunity.”
Troy Wilson, Ph.D., J.D., President and Chief Executive Officer